Erratum: Plant-based medicines for anxiety disorders, Part 2: A review of clinical studies with supporting preclinical evidence (CNS Drugs (2013) 27:4 (301-319) DOI:10.1007/s40263-013-0059-9);Plant-based medicines for anxiety disorders, part 2: A review of clinical studies with supporting preclinical evidence

CNS Drugs

Volumn 27, Issue 4, 2013, Pages 301-319

  Sarris, Jerome ^a,b   McIntyre, Erica ^c   Camfield, David A ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^c CHARLES STURT UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; BACOPA MONNIERI EXTRACT; CANNABIS; CENTELLA ASIATICA EXTRACT; DIAZEPAM; ECHIUM AMOENUM EXTRACT; FLUOXETINE; GALPHINIA GLAUCA EXTRACT; GINKGO BILOBA EXTRACT; HYPERICUM PERFORATUM EXTRACT; KAVA EXTRACT; MATRICARIA RECUTITA EXTRACT; MELISSA OFFICINALIS EXTRACT; PASSIFLORA INCARNATA EXTRACT; PSILOCYBE EXTRACT; PSYCHOTRIA VIRIDIS EXTRACT; RHODIOLA ROSEA EXTRACT; SALVIA MILTIORRHIZA EXTRACT; SCUTELLARIA LATERIFLORA EXTRACT; SILYBUM MARIANUM EXTRACT; SOUR ORANGE EXTRACT; UNCLASSIFIED DRUG; VALERIANA EXTRACT; WITHANIA SOMNIFERA EXTRACT; WITHANIA SOMNIFERUM EXTRACT;

AGORAPHOBIA; ANXIETY DISORDER; CENTELLA ASIATICA; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; ECHIUM AMOENUM; GALPHIMIA; GINKGO BILOBA; HERBAL MEDICINE; HUMAN; MATRICARIA; MEDICINAL PLANT; MELISSA OFFICINALIS; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; PASSIFLORA; PIPER METHYSTICUM; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVIEW; RHODIOLA ROSEA; SCUTELLARIA LATERIFLORA; SILYBUM MARIANUM; WITHANIA SOMNIFERUM;

EID: 84878258162     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0087-5     Document Type: Erratum

References (182)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th text revision ed. Arlington (VA): American Psychiatric Association; 2000.
2. Sarris J, McIntyre E, Camfield D. Plant-based medicines for anxiety disorders, part 1: A review of preclinical studies. CNS Drugs. 2013;27(3):207-19.
3. Sarris J. Herbal medicines in the treatment of psychiatric disorders: A systematic review. Phytother Res. 2007;21(8):703-16.
4. Sarris J, Kavanagh DJ. Kava and St John's wort: Current evidence for use in mood and anxiety disorders. J Altern Complement Med. 2009;15(8):827-36.
5. Spinella M. The psychopharmacology of herbal medicine: Plant drugs that alter mind, brain and behavior. Cambridge: MIT Press; 2001.
6. Awad R, Levac D, Cybulska P, et al. Effects of traditionally used anxiolytic botanicals on enzymes of the gamma-aminobutyric acid (GABA) system. Can J Physiol Pharmacol. 2007;85(9):933-42.
7. Kumar V. Potential medicinal plants for CNS disorders: An overview. Phytother Res. 2006;20(12):1023-35.
8. Sarris J, Panossian A, Schweitzer I, et al. Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence. Eur Neuropsychopharmacol. 2011;21(12):841-60.
9. Lakhan SE, Vieira KF. Nutritional and herbal supplements for anxiety and anxiety-related disorders: Systematic review. Nutr J. 2010;9:42.
10. Chen HC, Hsieh MT, Lai E. Studies on the suanzaorentang in the treatment of anxiety. Psychopharmacology (Berl). 1985;85(4):486-7.
11. Yuzurihara M, Ikarashi Y, Ishige A, et al. Anxiolytic-like effect of saiboku-to, an oriental herbal medicine, on histaminergics-induced anxiety in mice. Pharmacol Biochem Behav. 2000;67(3):489-95.
12. Kuribara H, Iwata H, Tomioka H, et al. The anxiolytic effect of Sho-ju-sen, a Japanese herbal medicine, assessed by an elevated plus-maze test in mice. Phytother Res. 2001;15(2):142-7.
13. Mantani N, Hisanaga A, Kogure T, et al. Four cases of panic disorder successfully treated with Kampo (Japanese herbal) medicines: Kami-shoyo-san and Hange-koboku-to. Psychiatry Clin Neurosci. 2002;56(6):617-20.
14. Lin YC, Hsieh MT, Chen CF, et al. Anxiolytic effect of ting-chih-wan in mouse behavior models of anxiety. Am J Chin Med. 2003;31(1):47-59.
15. Mizoguchi K, Ikeda R, Shoji H, et al. Saikokaryukotsuboreito, a herbal medicine, prevents chronic stress-induced anxiety in rats: Comparison with diazepam. J Nat Med. 2009;63(1):69-74.
16. Mizoguchi K, Tanaka Y, Tabira T. Anxiolytic effect of a herbal medicine, yokukansan, in aged rats: Involvement of serotonergic and dopaminergic transmissions in the prefrontal cortex. J Ethnopharmacol. 2010;127(1):70-6.
17. Wang HN, Peng Y, Tan QR, et al. Free and Easy Wanderer Plus (FEWP), a polyherbal preparation, ameliorates PTSD-like behavior and cognitive impairments in stressed rats. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(8):1458-63.
18. Meng XZ, Wu F, Wei PK, et al. A chinese herbal formula to improve general psychological status in posttraumatic stress disorder: A randomized placebo-controlled trial on sichuan earthquake survivors. Evid Based Complement Alternat Med. 2012;2012:691258.
19. Bhattacharya SK, Muruganandam AV. Adaptogenic activity of Withania somnifera: An experimental study using a rat model of chronic stress. Pharmacol Biochem Behav. 2003;75(3):547-55.
20. Mehta AK, Binkley P, Gandhi SS, et al. Pharmacological effects of Withania somnifera root extract on GABAA receptor complex. Indian J Med Res. 1991;94:312-5.
21. Bhattacharya SK, Bhattacharya A, Sairam K, et al. Anxiolytic- antidepressant activity of Withania somnifera glycowithanolides: An experimental study. Phytomedicine. 2000;7(6):463-9.
22. Andrade C, Aswath A, Chaturvedi SK, et al. A double-blind, placebo-controlled evaluation of the anxiolytic efficacy of an ethanolic extract of Withania somnifera. Indian J Psychiatry. 2000;42(3):295-301.
23. Russo A, Borrelli F. Bacopa monniera, a reputed nootropic plant: An overview. Phytomedicine. 2005;12(4):305-17.
24. Raghav SS, Dalal H, Srivastava PK, et al. Randomized controlled trial of standardized Bacopa monniera extract in age-associated memory impairment. Indian J Psychiatry. 2006;48:238-42.
25. Charles PD, Ambigapathy G, Geraldine P, et al. Bacopa monniera leaf extract up-regulates tryptophan hydroxylase (TPH2) and serotonin transporter (SERT) expression: Implications in memory formation. J Ethnopharmacol. 2011;134(1):55-61.
26. Singh HK, Dhawan BN. Neuropsychopharmacological effects of the ayurvedic nootropic Bacopa monniera Linn. Indian J Pharmacol. 1997;29(5):S359-65.
27. Chatterjee M, Verma P, Palit G. Comparative evaluation of Bacopa monniera and Panax quniquefolium in experimental anxiety and depressive models in mice. Indian J Exp Biol. 2010;48(3):306-13.
28. Pase M, Kean J, Sarris J, et al. The cognitive enhancing effects of Bacopa monneiri: A systematic review of randomized, controlled human clinical trials. J Altern Complement Med. 2012;18(7):647-52.
29. Calabrese C, Gregory WL, Leo M, et al. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: A randomized, double-blind, placebo-controlled trial. J Altern Complement Med. 2008;14(6):707-13.
30. Stough C, Lloyd J, Clarke J, et al. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology (Berl). 2001;156(4):481-4.
31. Bagetta G, Morrone LA, Rombola L, et al. Neuropharmacology of the essential oil of bergamot. Fitoterapia. 2010;81(6):453-61.
32. Saiyudthong S, Marsden CA. Acute effects of bergamot oil on anxiety-related behaviour and corticosterone level in rats. Phytother Res. 2011;25(6):858-62.
33. Akhlaghi M, Shabanian G, Rafieian-Kopaei M, et al. Citrus aurantium blossom and preoperative anxiety. Revista brasileira de anestesiologia. 2011;61(6):702-12.
34. Amsterdam JD, Li Y, Soeller I, et al. A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. J Clin Psychopharmacol. 2009;29(4):378-82.
35. Avallone R, Zanoli P, Puia G, et al. Pharmacological profile of apigenin, a flavonoid isolated from Matricaria chamomilla. Biochem Pharmacol. 2000;59(11):1387-94.
36. Awad R, Levac D, Cybulska P, et al. Effects of traditionally used anxiolytic botanicals on enzymes of the γ-aminobutyric acid (GABA) system. Can J Physiol Pharmacol. 2007;85(9):933-42.
37. Viola H, Wasowski C, Levi de Stein M, et al. Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Med. 1995;61(3):213-6.
38. Salgueiro JB, Ardenghi P, Dias M, et al. Anxiolytic natural and synthetic flavonoid ligands of the central benzodiazepine receptor have no effect on memory tasks in rats. Pharmacol Biochem Behav. 1997;58(4):887-91.
39. Zanoli P, Avallone R, Baraldi M. Behavioral characterisation of the flavonoids apigenin and chrysin. Fitoterapia. 2000;71(Suppl 1):S117-23.
40. Haller J, Hohmann J, Freund TF. The effect of Echinacea preparations in three laboratory tests of anxiety: Comparison with chlordiazepoxide. Phytother Res. 2010;24(11):1605-13.
41. Haller J, Freund TF, Pelczer KG, et al. The anxiolytic potential and psychotropic side effects of an echinacea preparation in laboratory animals and healthy volunteers. Phytother Res. 2013;27(1):54-61.
42. Gertsch J, Schoop R, Kuenzle U, et al. Echinacea alkylamides modulate TNF-alpha gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways. FEBS Lett. 2004;577(3):563-9.
43. Tambaro S, Bortolato M. Cannabinoid-related agents in the treatment of anxiety disorders: Current knowledge and future perspectives. Recent Pat CNS Drug Discov. 2012;7(1):25-40.
44. Rabbani M, Vaseghi G, Sajjadi SE, et al. Persian herbal medicines with anxiolytic properties. J Med Plant. 2011;10(39):7-11.
45. Sayyah M, Boostani H, Pakseresht S, et al. Efficacy of aqueous extract of Echium amoenum in treatment of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(8):1513-6.
46. Rabbani M, Sajjadi SE, Vaseghi G, et al. Anxiolytic effects of Echium amoenum on the elevated plus-maze model of anxiety in mice. Fitoterapia. 2004;75(5):457-64.
47. Jimenez-Ferrer E, Herrera-Ruiz M, Ramirez-Garcia R, et al. Interaction of the natural anxiolytic galphimine-B with serotonergic drugs on dorsal hippocampus in rats. J Ethnopharmacol. 2011;137(1):724-9.
48. Herrera-Ruiz M, Gonzalez-Cortazar M, Jimenez-Ferrer E, et al. Anxiolytic effect of natural galphimines from Galphimia glauca and their chemical derivatives. J Nat Prod. 2006;69(1):59-61.
49. Herrera-Ruiz M, Jimenez-Ferrer JE, De Lima TC, et al. Anxiolytic and antidepressant-like activity of a standardized extract from Galphimia glauca. Phytomedicine. 2006;13(1-2):23-8.
50. Herrera-Arellano A, Jimenez-Ferrer E, Zamilpa A, et al. Efficacy and tolerability of a standardized herbal product from Galphimia glauca on generalized anxiety disorder: A randomized, double-blind clinical trial controlled with lorazepam. Planta Med. 2007;73(8):713-7.
51. Herrera-Arellano A, Jiménez-Ferrer JE, Zamilpa A, et al. Therapeutic effectiveness of Galphimia glauca vs lorazepam in generalized anxiety disorder: A controlled 15-week clinical trial. Planta Medica. 2012;78(14):1529-35.
52. Bradwejn J, Zhou Y, Koszycki D, et al. A double-blind, placebo-controlled study on the effects of gotu kola (Centella asiatica) on acoustic startle response in healthy subjects. J Clin Psychopharmacol. 2000;20(6):680.
53. Wijeweera P, Arnason JT, Koszycki D, et al. Evaluation of anxiolytic properties of Gotu kola (Centella asiatica) extracts and asiaticoside in rat behavioral models. Phytomedicine. 2006;13(9-10):668-76.
54. Chen Y, Han T, Rui Y, et al. Effects of total triterpenes of Centella asiatica on the corticosterone levels in serum and contents of monoamine in depression rat brain. J Chin Med Mater (Zhongyaocai). 2005;28(6):492-6.
55. Bradwejn J, Zhou Y, Koszycki D, et al. A double-blind, placebo-controlled study on the effects of gotu kola (Centella asiatica) on acoustic startle response in healthy subjects. J Clin Psychopharmacol. 2000;20(6):680-4.
56. Jana U, Sur TK, Maity LN, et al. A clinical study on the management of generalized anxiety disorder with Centella asiatica. NMCJ. 2010;12(1):8-11.
57. Yoshitake T, Yoshitake S, Kehr J. The Ginkgo biloba extract EGb 761(R) and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex. Br J Pharmacol. 2010;159(3):659-68.
58. Fehske CJ, Leuner K, Muller WE. Ginkgo biloba extract (EGb761) influences monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity after chronic treatment. Pharmacol Res. 2009;60(1):68-73.
59. Kuribara H, Weintraub ST, Yoshihama T, et al. An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice. J Nat Prod. 2003;66(10):1333-7.
60. Woelk H, Arnoldt KH, Kieser M, et al. Ginkgo biloba special extract EGb 761((R)) in generalized anxiety disorder and adjustment disorder with anxious mood: A randomized, double-blind, placebo-controlled trial. J Psychiatr Res. 2007;41(6):472-80.
61. Koch E. Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides: Considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts. Phytomedicine. 2005;12(1-2):10-6.
62. Bilia AR, Gallon S, Vincieri FF. Kava-kava and anxiety: Growing knowledge about the efficacy and safety. Life Sci. 2002;70(22):2581-97.
63. Raduege KM, Kleshinski JF, Ryckman JV, et al. Anesthetic considerations of the herbal, kava. J Clin Anesth. 2004;16(4):305-11.
64. Singh YN, Singh NN. Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs. 2002;16(11):731-43.
65. Nerurkar PV, Dragull K, Tang CS. In vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones. Toxicol Sci. 2004;79(1):106-11.
66. Lebot V, Lévesque J. The origin and distribution of kava (Piper methysticum Forst. f. and Piper wichmannii C. DC., Piperaceae): A phytochemical approach. Allertonia. 1989;5:223-80.
67. Sarris J, LaPorte E, Schweitzer I. Kava: A comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiatry. 2011;45(1):27-35.
68. Magura EI, Kopanitsa MV, Gleitz J, et al. Kava extract ingredients, (+)-methysticin and (+/-)-kavain inhibit voltage-operated Na(+)-channels in rat CA1 hippocampal neurons. Neuroscience. 1997;81(2):345-51.
69. Gleitz J, Beile A, Peters T. (+/-)-Kavain inhibits veratridine-activated voltage-dependent Na(+)-channels in synaptosomes prepared from rat cerebral cortex. Neuropharmacology. 1995;34(9):1133-8.
70. Martin HB, McCallum M, Stofer WD, et al. Kavain attenuates vascular contractility through inhibition of calcium channels. Planta Med. 2002;68(9):784-9.
71. Walden J, von Wegerer J, Winter U, et al. Effects of kawain and dihydromethysticin on field potential changes in the hippocampus. Prog Neuropsychopharmacol Biol Psychiatry. 1997;21(4):697-706.
72. Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology (Berl). 1994;116(4):469-74.
73. Uebelhack R, Franke L, Schewe HJ. Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava). Pharmacopsychiatry. 1998;31(5):187-92.
74. Wu D, Yu L, Nair M, et al. Cyclooxygenase enzyme inhibitory compounds with antioxidant activities from Piper methysticum (kava kava) roots. Phytomedicine. 2002;9:41-7.
75. Baum SS, Hill R, Rommelspacher H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Prog Neuropsychopharmacol Biol Psychiatry. 1998;22(7):1105-20.
76. Seitz U, Schule A, Gleitz J. [3H]-monoamine uptake inhibition properties of kava pyrones. Planta Med. 1997;63(6):548-9.
77. Rex A, Morgenstern E, Fink H. Anxiolytic-like effects of kava-kava in the elevated plus maze test: A comparison with diazepam. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(5):855-60.
78. Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev. 2003(1):CD003383.
79. Sarris J, La Porte E, Schweitzer I. Kava: A comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiatry. 2011;45(1):27-35.
80. Sarris J, Kavanagh D, Byrne G, et al. The Kava Anxiety Depression Spectrum Study (KADSS): A randomized, placebo-controlled, cross-over trial using an aqueous extract of Piper methysticum. Psychopharmacology (Berl). 2009;205(3):399-407.
81. Sarris J, Scholey A, Schweitzer I, et al. The acute effects of kava and oxazepam on anxiety, mood, neurocognition, and genetic correlates: A randomized, placebo-controlled, double-blind study. Human Psychopharm. 2012;27(3):262-9.
82. Teschke R, Sarris J, Glass X, et al. Kava, the anxiolytic herb: Back to basics to prevent liver injury? Br J Clin Pharm. 2011;71(3):445-8.
83. Sarris J, Teschke R, Stough C, et al. Re-introduction of Kava (Piper methysticum) to the EU: Is there a way forward? Planta Med. 2011;77(2):107-10.
84. Cases J, Ibarra A, Feuillere N, et al. Pilot trial of Melissa officinalis L. leaf extract in the treatment of volunteers suffering from mild-to-moderate anxiety disorders and sleep disturbances. Med J Nutrition Metab. 2011;4(3):211-218.
85. Awad R, Muhammad A, Durst T, et al. Bioassay-guided fractionation of lemon balm (Melissa officinalis L.) using an in vitro measure of GABA transaminase activity. Phytother Res. 2009;23(8):1075-81.
86. Awad R, Muhammad A, Durst T, et al. Bioassay-guided fractionation of lemon balm (Melissa officinalis L.) using an in vitro measure of GABA transaminase activity. Phytotherapy Res. 2009;23(8):1075-81.
87. Yoo DY, Choi JH, Kim W, et al. Effects of Melissa officinalis L. (Lemon Balm) extract on neurogenesis associated with serum corticosterone and GABA in the mouse dentate gyrus. Neurochem Res. 2011;36(2):250-7.
88. Ibarra A, Feuillere N, Roller M, et al. Effects of chronic administration of Melissa officinalis L. extract on anxiety-like reactivity and on circadian and exploratory activities in mice. Phytomedicine. 2010;17(6):397-403.
89. Lopez V, Martin S, Gomez-Serranillos MP, et al. Neuroprotective and neurological properties of Melissa officinalis. Neurochem Res. 2009;34(11):1955-61.
90. Kennedy DO, Scholey AB, Tildesley NTJ, et al. Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacol Biochem Behav. 2002;72(4):953-64.
91. Kennedy DO, Little W, Scholey AB. Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis (lemon balm). Psychosom Med. 2004;66(4):607-13.
92. Sayyah M, Boostani H, Pakseresht S, et al. Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of obsessive-compulsive disorder. Prog NeuroPsychopharmacol Biol Psychiatry. 2010;34(2):362-5.
93. Osuchowski MF, Johnson VJ, He Q, et al. Alterations in regional brain neurotransmitters by silymarin, a natural antioxidant flavonoid mixture. BALB/c mice. Pharm Biol. 2004;42(4-5):384-9.
94. Lu P, Mamiya T, Lu L, et al. Silibinin attenuates cognitive deficits and decreases of dopamine and serotonin induced by repeated methamphetamine treatment. Behav Brain Res. 2010;207(2):387-93.
95. Mazzio EA, Harris N, Soliman KFA. Food constituents attenuate monoamine oxidase activity and peroxide levels in C6 astrocyte cells. Planta Medica. 1998;64(7):603-6.
96. Akhondzadeh S, Naghavi HR, Vazirian M, et al. Passionflower in the treatment of generalized anxiety: A pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther. 2001;26(5):363-7.
97. Dhawan K, Kumar S, Sharma A. Anxiolytic activity of aerial and underground parts of Passiflora incarnata. J Ethnopharmacol. 2001;72(8):922-6.
98. Dhawan K, Kumar S, Sharma A. Comparative biological activity study on Passiflora incarnata and P. edulis. Fitoterapia. 2001;72(6):698-702.
99. Awad R, Arnason JT, Trudeau V, et al. Phytochemical and biological analysis of skullcap (Scutellaria lateriflora L.): A medicinal plant with anxiolytic properties. Phytomedicine. 2003;10(8):640-9.
100. Dhawan K, Kumar S, Sharma A. Anti-anxiety studies on extracts of Passiflora incarnata linneaus. J Ethnopharmacol. 2001;78(2-3):165-70.
101. Brown E, Hurd NS, McCall S, et al. Evaluation of the anxiolytic effects of chrysin, a Passiflora incarnata extract, in the laboratory rat. AANA J. 2007;75(5):333-7.
102. de Castro PCF, Hoshino A, Silva JCd, et al. Possible anxiolytic effect of two extracts of Passiflora quadrangularis L. in experimental models. Phytotherapy Res. 2007;21(5):481-4.
103. Wolfman C, Viola H, Paladini A, et al. Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharmacol Biochem Behav. 1994;47(1):1-4.
104. Sampath C, Holbik M, Krenn L, et al. Anxiolytic effects of fractions obtained from Passiflora incarnata L. in the elevated plus maze in mice. Phytotherapy Res. 2011;25(6):789-95.
105. Dhawan K, Kumar S, Sharma A. Comparative anxiolytic activity profile of various preparations of Passiflora incarnata linneaus: A comment on medicinal plants' standardization. J Altern Comp Med. 2002;8(3):283-91.
106. Movafegh A, Alizadeh R, Hajimohamadi F, et al. Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: A double-blind, placebo-controlled study. Anesth Analg. 2008;106(6):1728-32.
107. Aslanargun P, Cuvas O, Dikmen B, et al. Passiflora incarnata Linneaus as an anxiolytic before spinal anesthesia. J Anesth. 2012;26(1):39-44.
108. Appel K, Rose T, Fiebich B, et al. Modulation of the γ-aminobutyric acid (GABA) system by Passiflora incarnata L. Phytotherapy Res. 2011;25(6):838-43.
109. Petry RD, Reginatto F, de-Paris F, et al. Comparative pharmacological study of hydroethanol extracts of Passiflora alata and Passiflora edulis leaves. Phytotherapy Res. 2001;15(2):162-4.
110. Grundmann O, Wahling C, Staiger C, et al. Anxiolytic effects of a passion flower (Passiflora incarnata L.) extract in the elevated plus maze in mice. Die Pharmazie. 2009;64(1):63-4.
111. Grundmann O, Wang J, McGregor GP, et al. Anxiolytic activity of a phytochemically characterized Passiflora incarnata extract is mediated via the GABAergic system. Planta Med. 2008;74(15):1769-73.
112. Barbosa PR, Valvassori SS, Bordignon CL, et al. The aqueous extracts of Passiflora alata and Passiflora edulis reduce anxiety-related behaviors without affecting memory process in rats. J Med Food. 2008;11(2):282-8.
113. Deng J, Zhou Y, Bai M, et al. Anxiolytic and sedative activities of Passiflora edulis f. flavicarpa. J Ethnopharmacol. 2010;128(1):148-53.
114. Li H, Zhou P, Yang Q, et al. Comparative studies on anxiolytic activities and flavonoid compositions of Passiflora edulis 'edulis' and Passiflora edulis 'flavicarpa'. J Ethnopharmacol. 2011;133(3):1085-90.
115. Lolli LF, Sato CM, Romanini CV, et al. Possible involvement of GABAA-benzodiazepine receptor in the anxiolytic-like effect induced by Passiflora actinia extracts in mice. J Ethnopharmacol. 2007;111(2):308-14.
116. Soulimani R, Younos C, Jarmouni S, et al. Behavioural effects of Passiflora incarnata L. and its indole alkaloid and flavonoid derivatives and maltol in the mouse. J Ethnopharmacol. 1997;57(1):11-20.
117. Akhondzadeh S, Naghavi HR, Vazirian M, et al. Passionflower in the treatment of generalized anxiety: A pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther. 2001;26(5):363-7.
118. Movafegh A, Alizadeh R, Hajimohamadi F, et al. Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: A double-blind, placebo-controlled study. Anesth Analg. 2008;106(6):1728-32.
119. Panossian A, Gabrielian E, Wagner H. On the mechanism of action of plant adaptogens with particular reference to Cucurbitacin R Diglucoside. Phytomedicine. 1999;6(3):147-55.
120. Panossian A, Wikman G, Sarris J. Rosenroot (Rhodiola rosea): Traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine. 2010;17(7):481-93.
121. Perfumi M, Mattioli L. Adaptogenic and central nervous system effects of single doses of 3% rosavin and 1% salidroside Rhodiola rosea L. extract in mice. Phytother Res. 2007;21(1):37-43.
122. Bystritsky A, Kerwin L, Feusner JD. A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD). J Altern Complement Med. 2008;14(2):175-80.
123. Perry NSL, Houghton PJ, Sampson J, et al. In-vitro activity of S. lavandulaefolia (Spanish sage) relevant to treatment of Alzheimer's disease. J Pharm Pharmacol. 2001;53(10):1347-56.
124. Kennedy DO, Dodd FL, Robertson BC, et al. Monoterpenoid extract of sage (Salvia lavandulaefolia) with cholinesterase inhibiting properties improves cognitive performance and mood in healthy adults. J Psychopharmacol. 2011;25(8):1088-100.
125. Herrera-Ruiz M, García-Beltrán Y, Mora S, et al. Antidepressant and anxiolytic effects of hydroalcoholic extract from Salvia elegans. J Ethnopharmacol. 2006;107(1):53-8.
126. Hosseinzadeh H, Danaee A, Ziaee T. Anti-anxiety effect of aqueous and ethanolic extracts of Salvia leriifolia Benth. leaves in mice using elevated plus maze. J Med Plant. 2008;7(27):25-36.
127. Rabbani M, Sajjadi SE, Jafarian A, et al. Anxiolytic effects of Salvia reuterana Boiss. on the elevated plus-maze model of anxiety in mice. J Ethnopharmacol. 2005;101(1-3):100-3.
128. Kennedy DO, Pace S, Haskell C, et al. Effects of cholinesterase inhibiting sage (Salvia officinalis) on mood, anxiety and performance on a psychological stressor battery. Neuropsychopharmacology. 2006;31(4):845-52.
129. Tildesley NTJ, Kennedy DO, Perry EK, et al. Positive modulation of mood and cognitive performance following administration of acute doses of Salvia lavandulaefolia essential oil to healthy young volunteers. Physiol Behav. 2005;83(5):699-709.
130. Wolfson P, Hoffmann D. An investigation into the efficacy of Scutellaria lateriflora in healthy volunteers. Altern Ther Health Med. 2003;9(2):74.
131. Li J, Wang Y-H, Smillie TJ, et al. Identification of phenolic compounds from Scutellaria lateriflora by liquid chromatography with ultraviolet photodiode array and electrospray ionization tandem mass spectrometry. J Pharml Biomed Anal. 2012;63:120-7.
132. Zhang Z, Lian X-y, Li S, et al. Characterization of chemical ingredients and anticonvulsant activity of American skullcap (Scutellaria lateriflora). Phytomedicine. 2009;16(5):485-93.
133. Kuroda M, Iwabuchi K, Mimaki Y. Chemical constituents of the aerial parts of Scutellaria lateriflora and their alpha-glucosidase inhibitory activities. Nat Prod Commun. 2012;7(4):471.
134. Yaghmai MS. Volatile constituents of Scutellaria lateriflora L. Flavour Fragr J. 1988;3(1):27-31.
135. de Carvalho RSM, Duarte FS, de Lima TCM. Involvement of GABAergic non-benzodiazepine sites in the anxiolytic-like and sedative effects of the flavonoid baicalein in mice. Behav Brain Res. 2011;221(1):75-82.
136. Hui KM, Huen MSY, Wang HY, et al. Anxiolytic effect of wogonin, a benzodiazepine receptor ligand isolated from Scutellaria baicalensis Georgi. Biochem Pharmacol. 2002;64(9):1415-24.
137. Wolfson P, Hoffmann D. An investigation into the efficacy of Scutellaria lateriflora in healthy volunteers. Altern Ther Health Med. 2003;9(2):74.
138. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: A meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(1):118-27.
139. Butterweck V, Schmidt M. St. John's wort: Role of active compounds for its mechanism of action and efficacy. Wiener Medizinische Wochenschrift. 2007;157(13-14):356-61.
140. Nathan PJ. Hypericum perforatum (St John's Wort): A non-selective reuptake inhibitor? A review of the recent advances in its pharmacology. J Psychopharmacol. 2001;15(1):47-54.
141. Taylor LH, Kobak KA. An open-label trial of St. John's Wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry. 2000;61(8):575-8.
142. Kobak KA, Taylor LV, Bystritsky A, et al. St John's wort versus placebo in obsessive-compulsive disorder: Results from a double-blind study. Int Clin Psychopharmacol. 2005;20(6):299-304.
143. Kobak KA, Taylor LV, Warner G, et al. St. John's wort versus placebo in social phobia: Results from a placebo-controlled pilot study. J Clin Psychopharmacol. 2005;25(1):51-8.
144. Gao XQ, Björk L. Valerenic acid derivatives and valepotriates among individuals, varieties and species of Valeriana. Fitoterapia. 2000;71(1):19-24.
145. Patočka J, Jakl J. Biomedically relevant chemical constituents of Valeriana officinalis. J Appl Biomed. 2010;8:11-8.
146. Muller CE, Schumacher B, Brattstrom A, et al. Interactions of valerian extracts and a fixed valerian-hop extract combination with adenosine receptors. Life Sci. 2002;71(16):1939-49.
147. Benke D, Barberis A, Kopp S, et al. GABA(A) receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts. Neuropharmacology. 2009;56(1):174-81.
148. Dunayev VV, Trzhetsinsky SD, Tishkin VS, et al. Biological activity of the sum of valepotriates isolated from Val. alliariifolia Adams. Farmakologiya i Toksikologiya. 1987;50(6):33-7.
149. Andreatini R, Leite JR. Effect of valepotriates on the behavior of rats in the elevated plus-maze during diazepam withdrawal. Eur J Pharmacol. 1994;260(2-3):233-5.
150. Miyasaka LS, Atallah AN, Soares BG. Valerian for anxiety disorders. Cochrane Database Syst Rev. 2006(4):CD004515.
151. Andreatini R, Sartori VA, Seabra MLV, et al. Effect of valepotriates (valerian extract) in generalized anxiety disorder: A randomized placebo-controlled pilot study. Phytotherapy Res. 2002;16(7):650-4.
152. Bos R, Hendriks H, Scheffer JJC, et al. Cytotoxic potential of valerian constituents and valerian tinctures. Phytomedicine. 1998;5(3):219-25.
153. Bounthanh C, Bergmann C, Beck JP, et al. Valepotriates, a new class of cytotoxic and antitumor agents. Planta Medica. 1981;41(1):21-8.
154. Bhattacharyya D, Jana U, Debnath PK, et al. Initial exploratory observational pharmacology of Valeriana wallichii on stress management: A clinical report. NMCJ. 2007;9(1):36-9.
155. Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology. 2011;218(4):649-65.
156. Passie T, Seifert J, Schneider U, et al. The pharmacology of psilocybin. Addict Biol. 2002;7(4):357-64.
157. Studerus E, Kometer M, Hasler F, et al. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies. J Psychopharmacol. 2011;25(11):1434-52.
158. Halberstadt AL, Geyer MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology. 2011;61(3):364-81.
159. Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport. 1998;9(17):3897-902.
160. Frokjaer VG, Mortensen EL, Nielsen FÅ, et al. Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder. Biol Psychiatry. 2008;63(6):569-76.
161. Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nat Rev Neurosci. 2010;11(9):642-51.
162. Grof S, Goodman L, Richards W, et al. LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacophsychiatry. 1973;8:129-44.
163. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68(1):71-8.
164. Brandrup E, Vanggaard T. LSD treatment in a severe case of compulsive neurosis. Acta Psychiatrica Scandinavica. 1977;55(2):127-41.
165. Moreno FA, Delgado PL. Hallucinogen-induced relief of obsessions and compulsions. Am J Psychiatry. 1997;154(7):1037-8.
166. Moreno FA, Wiegand CB, Taitano EK, et al. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(11):1735-40.
167. Matsushima Y, Shirota O, Kikura-Hanajiri R, et al. Effects of psilocybe argentipes on marble-burying behavior in mice. Biosci Biotechnol Biochem. 2009;73(8):1866-8.
168. Dobkin De Ríos M. Visionary vine: Psychedelic healing in the Peruvian Amazon. Int J Soc Psychiatry. 1972;17:256-69.
169. McKenna DJ. Clinical investigations of the therapeutic potential of ayahuasca: Rationale and regulatory challenges. Pharmacol Ther. 2004;102(2):111-29.
170. Riba J, Valle M, Urbano G, et al. Human pharmacology of ayahuasca: Subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther. 2003;306(1):73-83.
171. Grob CS, McKenna DJ, Callaway JC, et al. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis. 1996;184(2):86-94.
172. Callaway JC, Airaksinen MM, McKenna DJ, et al. Platelet serotonin uptake sites increased in drinkers of ayahuasca. Psychopharmacology. 1994;116(3):385-7.
173. Santos RG, Landeira-Fernandez J, Strassman RJ, et al. Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. J Ethnopharmacol. 2007;112(3):507-13.
174. Patton GC, Coffey C, Carlin JB, et al. Cannabis use and mental health in young people: Cohort study. BMJ. 2002;325(7374):1195-8.
175. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet. 2007;370(9584):319-28.
176. Campos AC, Guimarães FS. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology. 2008;199(2):223-30.
177. Resstel LBM, Tavares RF, Lisboa SFS, et al. 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol. 2009;156(1):181-8.
178. Bergamaschi MM, Queiroz RHC, Chagas MHN, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-nave social phobia patients. Neuropsychopharmacology. 2011;36(6):1219-26.
179. Zuardi AW, Cosme RA, Graeff FG, et al. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol. 1993;7(1):82-8.
180. Griffiths RR, Grob CS. Hallucinogens as medicine. Sci Am. 2010;303(6):77-9.
181. Ulrich-Merzenich G, Zeitler H, Jobst D, et al. Application of the "Omic" technologies in phytomedicine. Phytomedicine. 2007;14(1):70-82.
182. Sarris J, Ng C, Schweitzer I. "Omic" genetic technologies for herbal medicines in psychiatry. Phytother Res. 2012;26(4):522-7.